GSK-3β表达水平与胶质瘤患者预后的关系(1)
[摘要] 目的 分析糖原合成酶激酶-3β(GSK-3β)表达水平与胶质瘤患者预后的关系。 方法 收集2010年1月～2014年12月河北省唐山市人民医院接收手术治疗胶质瘤148患者的组织标本和临床病理资料。根据GSK-3β表达水平将其分为GSK-3β高表达组(85例)和GSK-3β低表达组(63例)。收集两组年龄、性别、肿瘤长径(<4 cm，≥4 cm)，肿瘤位置(额叶、颞叶、其他)，WHO分级资料，免疫组化检测GSK-3β在组织中的表达，Kaplan-Meier分析和Cox回归分析GSK-3β表达与胶质瘤患者的预后关系。 结果 GSK-3β表达水平与WHO分级明显相关(P < 0.05)。GSK-3β高表达组的总生存时间短于GSK-3β低表达组(HR=2.31，95%CI：1.87～4.15，P < 0.01)。GSK-3β高表达、WHO高分级是预后不良的影响因素。结论 GSK-3β高表达与胶质瘤患者的不良预后有关，是其不良预后的独立预测因子。
[关键词] 胶质瘤;糖原合成酶激酶-3β;预后;免疫组化
[中图分类号] R739.4 [文献标识码] A [文章编号] 1673-7210(2020)06(b)-0113-04
Relationship between GSK-3β and prognosis in patients with glioma
ZHAO Kai WANG Zhiwu YANG Junquan
The First Department of Chemoradiotherapy， Tangshan People′s Hospital， Hebei Province， Tangshan 063000， China
[Abstract] Objective To analyze the relationship between glycogen synthase kinase-3β (GSK-3β) expression and prognosis of glioma patients. Methods Tissue specimens and clinical pathological data of 148 cases who received surgical treatment for glioma in Tangshan People′s Hospital of Hebei Province from January 2010 to December 2014 were collected. According to the expression of GSK-3β， they were devided into GSK-3β high-expression group (85 cases) and GSK-3β low-expression group (63 cases). Age， gender， tumor length and diameter (<4 cm， ≥4 cm)， tumor location (frontal lobe， temporal lobe， others)， WHO grading data of two groups were collected. Immunohistochemical analysis of GSK-3β expression in tissues， Kaplan-Meier analysis and Cox regression analysis of the relationship between GSK-3β expression and the prognosis of glioma patients. Results GSK-3β expression level was significantly correlated with WHO grade (P < 0.05). The total survival time of GSK-3β high-expression group was shorter than that of GSK-3β low-expression group (HR=2.31， 95%CI： 1.87-4.15， P < 0.01). High GSK-3β expression and WHO grade were the factors affecting poor prognosis. Conclusion The high expression of GSK-3β is related to the poor prognosis of glioma patients， and it is an independent predictor of poor prognosis.
[Key words] Glioma; Glycogen synthetase kinase-3β; Prognosis; Immunohistochemistry
胶质瘤是成人原发性脑肿瘤中最具侵袭性的类型，包括星形细胞瘤、少突胶质细胞瘤、少突-星形膠质瘤细胞和室管膜瘤[1]。胶质瘤又可分为WHO Ⅰ、Ⅱ、Ⅲ和Ⅳ级，级别越高，恶性程度越高;对于WHO Ⅳ级胶质瘤患者，中位生存时间只有12～15个月，对于Ⅲ级和低级别(Ⅰ和Ⅱ级)胶质瘤患者，生存期虽然可超过两年，但因为其具有高度侵袭性和对治疗的抵抗，预后也不尽如意[2-3]。尽管临床实践中已经运用多种策略，包括通过预测工具、分子和遗传信息来辅助胶质瘤的诊治管理，但肿瘤进展和复发风险仍然是一个重要问题。近5年来，胶质瘤的治疗方法有所改进，但患者的中位生存率并不令人满意。因此，有必要探索新的癌症相关基因，来作为胶质瘤治疗预后标志物[4]。, 百拇医药(赵凯 王志武 杨俊泉)
[关键词] 胶质瘤;糖原合成酶激酶-3β;预后;免疫组化
[中图分类号] R739.4 [文献标识码] A [文章编号] 1673-7210(2020)06(b)-0113-04
Relationship between GSK-3β and prognosis in patients with glioma
ZHAO Kai WANG Zhiwu YANG Junquan
The First Department of Chemoradiotherapy， Tangshan People′s Hospital， Hebei Province， Tangshan 063000， China
[Abstract] Objective To analyze the relationship between glycogen synthase kinase-3β (GSK-3β) expression and prognosis of glioma patients. Methods Tissue specimens and clinical pathological data of 148 cases who received surgical treatment for glioma in Tangshan People′s Hospital of Hebei Province from January 2010 to December 2014 were collected. According to the expression of GSK-3β， they were devided into GSK-3β high-expression group (85 cases) and GSK-3β low-expression group (63 cases). Age， gender， tumor length and diameter (<4 cm， ≥4 cm)， tumor location (frontal lobe， temporal lobe， others)， WHO grading data of two groups were collected. Immunohistochemical analysis of GSK-3β expression in tissues， Kaplan-Meier analysis and Cox regression analysis of the relationship between GSK-3β expression and the prognosis of glioma patients. Results GSK-3β expression level was significantly correlated with WHO grade (P < 0.05). The total survival time of GSK-3β high-expression group was shorter than that of GSK-3β low-expression group (HR=2.31， 95%CI： 1.87-4.15， P < 0.01). High GSK-3β expression and WHO grade were the factors affecting poor prognosis. Conclusion The high expression of GSK-3β is related to the poor prognosis of glioma patients， and it is an independent predictor of poor prognosis.
[Key words] Glioma; Glycogen synthetase kinase-3β; Prognosis; Immunohistochemistry
胶质瘤是成人原发性脑肿瘤中最具侵袭性的类型，包括星形细胞瘤、少突胶质细胞瘤、少突-星形膠质瘤细胞和室管膜瘤[1]。胶质瘤又可分为WHO Ⅰ、Ⅱ、Ⅲ和Ⅳ级，级别越高，恶性程度越高;对于WHO Ⅳ级胶质瘤患者，中位生存时间只有12～15个月，对于Ⅲ级和低级别(Ⅰ和Ⅱ级)胶质瘤患者，生存期虽然可超过两年，但因为其具有高度侵袭性和对治疗的抵抗，预后也不尽如意[2-3]。尽管临床实践中已经运用多种策略，包括通过预测工具、分子和遗传信息来辅助胶质瘤的诊治管理，但肿瘤进展和复发风险仍然是一个重要问题。近5年来，胶质瘤的治疗方法有所改进，但患者的中位生存率并不令人满意。因此，有必要探索新的癌症相关基因，来作为胶质瘤治疗预后标志物[4]。, 百拇医药(赵凯 王志武 杨俊泉)